Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 2/20 | 0.51 |
| ▸ | TK1 | P04183 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1857100 | 0.86 | TYMS (0.53) | TYMSTK1POLB | |
| SCHEMBL288450 | 0.80 | TK1 (0.56) | TYMSTK1POLB | |
| SCHEMBL6386144 | 0.80 | TK1 (0.48) | TYMSTK1POLB | |
| Doxribtimine SCHEMBL20797965 | 0.79 | TYMS (0.63) | TYMSTK1POLB | |
| SCHEMBL7038113 | 0.78 | TK1 (0.49) | TYMSTK1 | |
| SCHEMBL7201324 | 0.78 | TK1 (0.60) | TYMSTK1POLB | |
| SCHEMBL25752637 | 0.78 | TK1 (0.60) | TYMSTK1POLB | |
| SCHEMBL25700727 | 0.78 | TK1 (0.60) | TYMSTK1POLB | |
| SCHEMBL25756099 | 0.78 | TK1 (0.60) | TYMSTK1POLB | |
| SCHEMBL3063249 | 0.78 | TYMS (0.68) | TYMSTK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190092874-A1 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | AGENSYS INC (US) | 2019-03-28 | — | — | US | disclosed |
| US-20160176977-A1 | NOVEL ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | AGENSYS, INC. | 2016-06-23 | — | — | US | disclosed |
| US-8846043-B2 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer | AGENSYS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140051838-A1 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | AGENSYS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8562989-B2 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer | AGENSYS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| EP-1537140-B1 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | AGENSYS INC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20110287016-A1 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | AGENSYS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-7977062-B2 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer | AGENSYS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2302041-A1 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer | Agensys, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20100158934-A1 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | AGENSYS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20070004913-A1 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer | AGENSYS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-7067130-B2 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer | AGENSYS, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-20060002993-A1 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer | AGENSYS, INC. | 2006-01-05 | — | — | US | disclosed |
| US-20050265924-A1 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer | AGENSYS, INC. | 2005-12-01 | — | — | US | disclosed |
| US-20050265921-A1 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer | AGENSYS, INC. | 2005-12-01 | — | — | US | disclosed |
| EP-1537140-A2 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | Agensys, Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20030206905-A1 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer | AGENSYS, INC. | 2003-11-06 | — | — | US | disclosed |
| US-20030191073-A1 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer | AGENSYS, INC. | 2003-10-09 | — | — | US | disclosed |
| WO-2003040340-A9 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | AGENSYS INC (US) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003040340-A2 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | AGENSYS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110287016-A1 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | DCLRE1B, PABPC1, PABPC4 | TYMS 1468/4885TK1 1759/4885POLB 558/4885 |
| US-20100158934-A1 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | DCLRE1B, PABPC1, PABPC4 | TYMS 1468/4885TK1 1759/4885POLB 558/4885 |
| US-20140051838-A1 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | DCLRE1B, PABPC1, PABPC4 | TYMS 1468/4885TK1 1759/4885POLB 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.